MT-7117

Phase 3Small molecule

TTanabe Pharma America, Inc.

MT-7117 is one of 42 small molecule programs targeting Erythropoietic Protoporphyria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erythropoietic ProtoporphyriaActive, not recruiting

Systemic SclerosisActive, not recruiting

Erythropoietic ProtoporphyriaPhase 3

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

3 2

Actemra

Roche

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Ofev

Boehringer Ingelheim

Phase 3

1 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Erythropoietic Protoporphyria

NCT05005975

Clinical

Trials by Indication[1]

Erythropoietic Protoporphyria3 trials

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Completed·TTanabe Pharma America, Inc.·Phase 2·NCT03520036·102 enrolled

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Completed·TTanabe Pharma America, Inc.·Phase 3·NCT04402489·184 enrolled

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Recruiting·TTanabe Pharma America, Inc.·Phase 3·NCT05005975·301 enrolled

Interaction2 trials

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04793295·112 enrolled

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT03688022·50 enrolled

Tics2 trials

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT02834442·144 enrolled

The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT06994286·40 enrolled

Systemic Sclerosis1 trial

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Completed·TTanabe Pharma America, Inc.·Phase 2·NCT04440592·76 enrolled

Oral1 trial

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT05241535·29 enrolled

3 more indications

Renal Impairment1 trial

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04656795·32 enrolled

Hepatic Function1 trial

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT04116476·23 enrolled

Unspecified1 trial

Mass Balance Study With MT-7117

Completed·TTanabe Pharma America, Inc.·Phase 1·NCT03503266·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for MT-7117. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MT-7117 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MT-7117. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanabe Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTanabe Pharma America, Inc.

MT-7117

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Erythropoietic Protoporphyria3 trials

Interaction2 trials

Tics2 trials

Systemic Sclerosis1 trial

Oral1 trial

Renal Impairment1 trial

Hepatic Function1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News